LATEST DEVELOPMENTS

In Febraury 2022, UK’s Small Pharma announced positive phase I result of World’s first clinical trial for DMT-Assisted therapy in major depressive disorder.

In January 2022, US’ PsyMed Ventures, announced its new $25 million investment fund. The money will go to early-stage startups, primarily those working on psychedelics, to help treat mental ailments.

In January 2022, Australian government announced $15 million grant for psychedelic clinical trials to treat mental illness.

In January 2022, Canada’s Awakn Life Sciences and US’ The Multidisciplinary Association for Psychedelic Studies (MAPS) partnered for MDMA-assisted therapy for treatment of alcohol use disorder in Europe.

In November 2021, Cybin and the University of Washington started a Phase 2 trial of psilocybin for COVID-related distress.

In September 2021, US’ Johns Hopkins researchers received federal grant to study psilocybin for smoking cessation.

In July 2021, US’ Harvard Law School’s PetrieFlom Centre launched research initiative to advance evidence-based psychedelics law and policy.

In June 2021, German startup Atai Life Sciences announced its IPO and raised $200 million. Atai became the third biotech company focused on psychedelic treatment for mental health disorders to list on a major US stock exchange after Canada’s MindMed and UK’s Compass Pathways, both went public in 2020.

In May 2021, US’ MAPS announced the positive results from world’s first Phase 3 clinical study on MDMA for the treatment of post-traumatic stress disorder.